Leiomyosarcoma
Leiomyosarcoma is an uncommon cancer that begins in smooth muscle — the kind of muscle that lines blood vessels, the gut, and the wall of the uterus. It can be a frightening diagnosis to receive, but with a team that sees these tumours regularly, there is a clear path: careful imaging, the right biopsy, surgery where possible, and modern systemic treatments to back it up.
What leiomyosarcoma is — in plain words
Your body contains two main kinds of muscle. Skeletal muscle — the muscle you can flex in your arm or leg — is under your conscious control. Smooth muscle works quietly in the background: it lines the wall of your blood vessels and squeezes them, it moves food through your intestines, it pushes a baby through labour. Leiomyosarcoma is a cancer of that quiet, involuntary smooth muscle.
Because smooth muscle is found in so many places in the body, leiomyosarcoma can arise in very different locations — and the location matters a great deal. A uterine leiomyosarcoma, a leiomyosarcoma of the inferior vena cava, and a leiomyosarcoma of the thigh share the same name, but they present differently, are operated on differently, and have different outlooks. The principles, however, are the same.
Leiomyosarcoma is part of the wider family of soft-tissue sarcomas and benefits from being looked after by a sarcoma multidisciplinary team from the very first decision.
Where leiomyosarcoma tends to appear
The uterus
Uterine leiomyosarcoma is a distinct entity in its own right. It is often discovered after a hysterectomy done for what was thought to be a benign fibroid. It tends to affect women in their forties and fifties.
The retroperitoneum and great vessels
Especially the wall of the inferior vena cava — the large vein that drains blood from the lower half of the body back to the heart. These are technically demanding tumours and need a specialist vascular and sarcoma team.
The deep soft tissue of the limbs
Usually arising from the wall of a small blood vessel deep within the muscle of an arm or, more often, a leg. Presents as a deep, painless lump.
Who tends to get leiomyosarcoma
Leiomyosarcoma is rare. It is mainly a disease of middle-aged and older adults — the average age at diagnosis is in the fifties or sixties — though it can occur earlier. Uterine leiomyosarcoma is, by definition, a disease of women; the other forms affect men and women roughly equally. There is no strong known cause for most cases. Previous radiation to the area is one recognised risk factor; certain rare inherited conditions slightly increase the risk.
Signs and symptoms — they depend on where the tumour is
Uterine leiomyosarcoma
Abnormal vaginal bleeding — heavier or more irregular than usual, or bleeding after the menopause. A growing pelvic mass. A fibroid that is genuinely enlarging after the menopause (when fibroids usually shrink) deserves careful evaluation.
Retroperitoneal leiomyosarcoma
Often very vague — abdominal discomfort, fullness, a swollen leg if the inferior vena cava is involved, sometimes the tumour is found incidentally on a scan done for an unrelated reason.
Leiomyosarcoma of the limb
A deep, firm, painless lump that has been slowly growing. Often noticed only when it becomes large enough to feel or see.
Less common sites
Skin (cutaneous leiomyosarcoma — usually less aggressive), the gut (often hard to distinguish from a GIST without proper testing), and rarely the heart or the great vessels in the chest.
"A fibroid that behaves like a fibroid almost always is one. But a 'fibroid' that grows after menopause, or that the surgeon describes as unusual at operation, deserves an honest second look. A small minority will turn out to be leiomyosarcoma — and catching that early changes everything."
How leiomyosarcoma is diagnosed
The workup is similar to other soft-tissue sarcomas, but adjusted for the location.
- Imaging of the primary site — MRI is the best scan for limb tumours and for pelvic uterine masses, while CT is the workhorse for retroperitoneal tumours and for tumours of the great vessels.
- CT scan of the chest, abdomen and pelvis — leiomyosarcoma spreads more readily than some other sarcomas. The lungs and the liver are the two commonest sites; full body staging is part of the workup.
- Image-guided core-needle biopsy — for limb and retroperitoneal tumours, planned along a path that the surgeon can later remove. For uterine leiomyosarcoma, the diagnosis is often made after hysterectomy, when the pathologist examines the removed uterus; in that case, no separate biopsy is needed, but the original specimen should be reviewed by a sarcoma-experienced pathologist.
- Specialist pathology — leiomyosarcoma can be confused with a benign smooth-muscle tumour (a leiomyoma) at the edges, particularly in the uterus. A pathologist who reports sarcomas regularly should review the slides.
How we treat leiomyosarcoma
As with all sarcomas, treatment is a team decision. A sarcoma surgeon (sometimes a gynaecological oncologist, a vascular surgeon, or both), a medical oncologist, a radiation oncologist, a pathologist, and a radiologist all review the case together.
Surgery — the mainstay
For nearly every localised leiomyosarcoma, surgery is the main treatment, and the aim is complete removal with a margin of normal tissue around the tumour.
- Uterine leiomyosarcoma is treated with hysterectomy, often together with removal of the ovaries and tubes. If a previous hysterectomy was done for what was thought to be a fibroid, further surgery may be needed.
- Retroperitoneal and vascular leiomyosarcoma may need extensive operations, sometimes including reconstruction of a major vein or removal of a kidney, performed at a specialist centre.
- Limb leiomyosarcoma is almost always treated with limb-sparing wide excision, removing the tumour with a cuff of normal tissue around it.
Chemotherapy
Leiomyosarcoma is moderately chemosensitive, and chemotherapy plays a real role in several situations.
- Adjuvant chemotherapy (after surgery) is considered for high-grade, large, or deeply seated tumours — the standard backbone is doxorubicin, sometimes combined with ifosfamide. For uterine leiomyosarcoma, combinations such as gemcitabine and docetaxel are also widely used.
- For metastatic disease, there are now several lines of treatment, including doxorubicin, gemcitabine-docetaxel, trabectedin, eribulin, and pazopanib. The order of these treatments is tailored to each patient, and many people stay well on systemic therapy for years.
Read more about chemotherapy →
Radiation therapy
Radiation is used selectively in leiomyosarcoma — most commonly for limb tumours where it is added before or after surgery to reduce the chance of local recurrence, and occasionally for selected uterine and retroperitoneal cases. It is also used to control symptoms from a particular site of disease, such as a painful bone metastasis.
Targeted therapy and the wider toolkit
Several drugs target growth signals in leiomyosarcoma. Pazopanib, a tablet, can hold the disease stable for months at a time. Newer agents are emerging from clinical trials. For oligometastatic disease — a small number of lung or liver metastases — surgery or stereotactic radiation can sometimes achieve long periods of disease control.
What the outlook honestly looks like
The outlook for leiomyosarcoma depends on the location, the size, the grade, and whether surgery achieved clear margins.
- Small, localised, completely removed leiomyosarcomas of the limb often have a long-term outlook above 60%.
- Uterine leiomyosarcoma has a more variable outlook depending on stage — confined to the uterus, five-year survival is around 50–60%; when the cancer has spread beyond the uterus, the figure is lower, but modern systemic treatment continues to shift it upwards.
- Retroperitoneal and vascular leiomyosarcomas are technically harder to remove completely; the outlook reflects how complete the surgery was.
- Metastatic disease is, in most cases, not currently curable — but it is very treatable. Many patients live well for several years with sequential lines of systemic treatment, sometimes interleaved with surgery or radiation for specific sites.
Numbers are averages — they do not predict any individual's outcome. We will always be honest with you about the realistic range for your particular situation.
Life during treatment
For a localised leiomyosarcoma, surgery is usually the most demanding part — recovery takes weeks to a couple of months depending on the operation. Most people return to ordinary life and ordinary work. When chemotherapy is added, the treatment period is typically four to six months, with manageable side-effects in most cases — hair loss, fatigue, a higher risk of infection during the low-count days, and nausea that we can almost always control.
For people on long-term systemic therapy for metastatic disease, the rhythm is different — life is built around regular treatment days, scans every few months, and the small adjustments needed to live well in between. Many of our patients on this kind of therapy continue to work, travel, look after grandchildren, and live normally for years.
After treatment — long-term follow-up
Because leiomyosarcoma can return — sometimes years after the original surgery — follow-up continues for a long time:
- Clinical review and examination of the primary site every 3–4 months for the first 2–3 years, then less often.
- CT scan of the chest, abdomen and pelvis every 6 months for the first 2–3 years, then yearly to year 5, and less often thereafter.
- For uterine leiomyosarcoma, follow-up includes pelvic examination and imaging at the same intervals.
Read about survivorship care →
The most important things to take away
- Leiomyosarcoma is uncommon, and the right team makes a real difference to the outcome.
- A "fibroid" that grows after menopause or that the surgeon describes as unusual deserves specialist pathology review.
- Surgery is the foundation. Adjuvant chemotherapy and selective radiation reduce the chance of return.
- Even when the disease has spread, there are multiple lines of effective systemic treatment — many patients live well for years.
Just been told it is leiomyosarcoma? Bring your reports.
We will go through the scans and the pathology with you, explain exactly what kind of leiomyosarcoma it is and where it sits, and help you get to the right surgical and oncology team for the next step. No rush, no jargon.
Medically reviewed by
Dr. Rehan Abdullah
Dr. Rehan Abdullah is a dual-trained clinical and radiation oncologist with over a decade of experience treating both solid tumours and hematologic malignancies. He serves as Consultant Oncologist at INMOL Hospital and sees patients at Farooq Hospital and Healthnox Medical Center, Lahore. Read full profile →
This page is patient education, not a substitute for an in-person consultation. Cancer care must be individualised. Read our medical disclaimer →